Change is on the horizon in the management of uveal melanoma
Novel strategies are offering the possibility of extended patient survival and durable disease control
Sustained benefits of neoadjuvant immunotherapy demonstrated in resectable melanoma
Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies
A novel off-the-shelf cancer vaccine shows some potential in PD-L1-negative patients with advanced melanoma
Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
What is the role of adjuvant immunotherapy in contemporary melanoma care?
Adjuvant immunotherapy is still actual despite heterogeneity on its accessibility in Europe and fast advances in neoadjuvant immunotherapy
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Next steps for research include personalising regimens and learning how to predict response and toxicity
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Adjuvant immunotherapy continues to confirm its efficacy in melanoma
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
Questions still remain on optimal adjuvant therapy in advanced melanoma
Overall survival benefits of systemic therapy in the adjuvant setting are still unclear in clinical trials, and may need to be complemented with real-world studies